ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CGEN Compugen Ltd

2.155
0.045 (2.13%)
Last Updated: 14:48:24
Delayed by 15 minutes
Share Name Share Symbol Market Type
Compugen Ltd NASDAQ:CGEN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.045 2.13% 2.155 2.15 2.16 2.17 2.14 2.17 22,630 14:48:24

Compugen Fourth Quarter and Year-End 2014 Conference Call Scheduled for Tuesday, February 10, 2015 at 10:00 AM EST

03/02/2015 12:09pm

Business Wire


Compugen (NASDAQ:CGEN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Compugen Charts.

Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EST on Tuesday, February 10, 2015 to review fourth quarter and year-end 2014 results. Compugen participants on the conference call will include Martin Gerstel, Chairman; Dr. Anat Cohen-Dayag, President and CEO; and Ari Krashin, CFO. The quarterly and year-end results will be released on the Company’s website (www.cgen.com), prior to the call.

To access the conference call, please dial 1-888-668-9141 from the US, or +972-3-918-0609 internationally. The call will also be available via live webcast through Compugen’s website, located at the following link.

A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the US or +972-3-925-5904 internationally. The replay will be available through February 12, 2015.

About Compugen

Compugen is a leading drug discovery company focused on monoclonal antibodies and therapeutic proteins to address important unmet needs in the fields of oncology and immunology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of novel drug target candidates, which are then advanced in its Pipeline Program. The discovery and development of monoclonal antibody therapeutic candidates against selected Compugen-discovered novel target candidates is performed by Compugen’s wholly-owned U.S. subsidiary located in South San Francisco. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. For additional information, please visit Compugen's corporate website at www.cgen.com.

Compugen Ltd.Tsipi Haitovsky, +972-52-598-9892Global Media Liaisontsipih@cgen.com

1 Year Compugen Chart

1 Year Compugen Chart

1 Month Compugen Chart

1 Month Compugen Chart

Your Recent History

Delayed Upgrade Clock